Targeted Combination Wins in KRAS-Positive Metastatic Colorectal Cancer
(MedPage Today) -- MADRID -- The combination of a KRAS G12C inhibitor and an EGFR inhibitor significantly improved progression-free survival (PFS) compared with standard treatment in patients with chemorefractory metastatic colorectal cancer... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 23, 2023 Category: Gastroenterology Source Type: news
Two Multitarget Stool Tests Show Promise for CRC Screening Two Multitarget Stool Tests Show Promise for CRC Screening
Two noninvasive tests in development, one measuring RNA and the other DNA, show high sensitivity for detection of colorectal cancer.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 22, 2023 Category: Internal Medicine Tags: Gastroenterology News Source Type: news
Potentially Unnecessary CRC Screening in Older Adults: Study Potentially Unnecessary CRC Screening in Older Adults: Study
A study found that adults with limited life expectancy often undergo colon cancer screening, raising concerns about inappropriate screening.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 22, 2023 Category: Cancer & Oncology Tags: Gastroenterology News Source Type: news
More Serious Adverse Events Seen With Debulking + Systemic Therapy in Metastatic CRC
FRIDAY, Oct. 20, 2023 -- For patients with multiorgan metastatic colorectal cancer (mCRC), adding maximum tumor debulking to systemic therapy is associated with more serious adverse events but no difference in health-related quality of life (HRQoL),... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 20, 2023 Category: Pharmaceuticals Source Type: news
New Trials in Colorectal Cancer: Could Your Patient Benefit? New Trials in Colorectal Cancer: Could Your Patient Benefit?
Maybe one of your patients can join a new clinical trial in colorectal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 19, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
F-Hb Concentration in FIT May Stratify CRC Risk in Elderly F-Hb Concentration in FIT May Stratify CRC Risk in Elderly
Fecal hemoglobin concentration in a negative FIT test may help stratify the risk for colorectal cancer in patients aged 75 years or older, suggests a study.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 17, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Harvard scientists studying rise of colorectal cancers in young people find 'surprising' link to BREAST MILK
Researchers from Missouri and Massachusetts found being breastfed as an infant was associated with an up to 40 percent higher chance of being diagnosed with colon cancer before the age of 55. (Source: the Mail online | Health)
Source: the Mail online | Health - October 16, 2023 Category: Consumer Health News Source Type: news
PET tracer targets KRAS mutations in cancer patients
In this study, the researchers tested the tracer in mice, and then for the first time in humans. They enrolled eight patients with lung cancer and six with colon cancer with KRAS mutations. Patients were injected with the tracer and then underwent hybrid PET/CT imaging.According to the findings, F-18 PFPMD-PET showed varied uptake in KRAS mutation tumors, and the SUVmax (uptake of the tracer by tumors) was significantly higher than in non-KRAS mutation tumors.In addition, the tracer uptake increase was generally consistent between the patients (+56.1%) and animal (+59.1%) studies, indicating that F-18 PFPMD is highly selec...
Source: AuntMinnie.com Headlines - October 16, 2023 Category: Radiology Authors: Will Morton Tags: Molecular Imaging Source Type: news
EXCLUSIVE Tragic victims of America's young colon cancer epidemic: From 'healthy' father killed at 29 to make-up artist, 35, whose stage three tumor was misdiagnosed three times
While cancers have steadily fallen over recent decades, scientists have been mystified by an explosion of colorectal cancer cases, also known as colon cancer, in younger adults. (Source: the Mail online | Health)
Source: the Mail online | Health - October 15, 2023 Category: Consumer Health News Source Type: news
GE HealthCare and Sophie ink deal to develop FAPI-PET tracers
GE HealthCare has established a licensing agreement to commercialize two fibroblast activated protein inhibitor (FAPI)-PET radiotracers developed by Sophie Biosciences for cancer imaging.Under the agreement, GE HealthCare will take on global rights for gallium-68 (Ga-68) FAPI-46 and outside-U.S. rights for F-18 FAPI-74, originally developed at Heidelberg University in Germany. Sofie will continue its clinical development and commercialization program with F-18 FAPI-74 in the U.S., according to a release.Both tracers are currently in phase II clinical trials in the U.S. The PET imaging radiotracers target cancer-associated ...
Source: AuntMinnie.com Headlines - October 11, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Lunit to showcase AI research at ESMO 2023
AI developer Lunit will present nine studies featuring the company's AI pathology technology at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain, being held October 20 to 24, 2023.The abstracts will cover a variety of areas and include the following:AI for prediction of multiple druggable mutations in non-small cell lung cancer from H&E stained imagesLunit Scope IO for distinguishing mismatch repair deficiency from mismatch repair proficiency colon cancers by analyzing features in whole slide imagesAI investigating the efficacy and safety of avelumab plus gemcitabine in leiomyosarcom...
Source: AuntMinnie.com Headlines - October 10, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
PLCOm2012 Models Have High Sensitivity for Lung Cancer
TUESDAY, Oct. 10, 2023 -- Two versions of the PLCOm2012 risk ‐prediction model (based on the 2012 Prostate, Lung, Colorectal, and Ovarian [PLCO] Cancer Screening Trial), with and without a predictor for race, have high sensitivities for lung... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 10, 2023 Category: Pharmaceuticals Source Type: news
Can interventions help improve timely follow-up exams?
A multilevel primary care intervention can improve timely follow-up of overdue abnormal cancer screening test results for several cancers, according to research published October 10 in JAMA. A team led by Steven Atlas, MD, from Massachusetts General Hospital in Boston found that their intervention, which includes electronic health record (EHR) reminders and patient outreach with or without patient navigation, found higher rates of follow-up completion within 120 days and 240 days of enrollment for breast, lung, cervical, and colorectal cancers compared with usual care. “We believe that such systems are best based in pr...
Source: AuntMinnie.com Headlines - October 10, 2023 Category: Radiology Authors: Amerigo Allegretto Tags: Practice Management Careers Imaging Leaders Source Type: news
Woman cured of bowel cancer in 6 months after receiving new drug
A 42-year-old woman had no evidence of cancer after receiving the drug dostarlimab which is still in early trials for treatment of a rare form of colorectal cancer. Carrie Downey, a single mother to a 17-year-old son, was diagnosed with bowel cancer a year ago but now, after just six months of…#carriedowney #mmr #downey #drcraigbarrington #iv #wales #gsk #fda (Source: Reuters: Health)
Source: Reuters: Health - October 9, 2023 Category: Consumer Health News Source Type: news
UK woman declared cancer-free, thanks to new 'miracle drug'
A civil servant in Wales has become the first person in the country to be prescribed a new drug, dostarlimab, for colorectal cancer. The 42-year-old was diagnosed with bowel cancer a year ago and received dostarlimab infusions for six months. Tests have shown that there is no longer any evidence of the disease. (Source: The Economic Times)
Source: The Economic Times - October 8, 2023 Category: Consumer Health News Source Type: news